The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis.
Saved in:
| Title: | The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis. |
|---|---|
| Authors: | Alten, Rieke1 (AUTHOR) Rieke.Alten@schlosspark-klinik.de, Burmester, Gerd R.2 (AUTHOR), Matucci-Cerinic, Marco3,4 (AUTHOR), Salmon, Jean-Hugues5,6 (AUTHOR), Lopez-Romero, Pedro7 (AUTHOR), Fakhouri, Walid7 (AUTHOR), de la Torre, Inmaculada7 (AUTHOR), Zaremba-Pechmann, Liliana8 (AUTHOR), Holzkämper, Thorsten7 (AUTHOR), Fautrel, Bruno9,10 (AUTHOR) |
| Source: | Rheumatology & Therapy. Feb2023, Vol. 10 Issue 1, p73-93. 21p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 21986576 |
|---|---|
| DOI: | 10.1007/s40744-022-00500-6 |
